Raymond James & Associates’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $83.6K | Sell |
50,657
-6,220
| -11% | -$12.6K | ﹤0.01% | 3803 |
|
|
2024
Q2 | $126K | Hold |
56,877
| – | – | ﹤0.01% | 3698 |
|
|
2024
Q1 | $152K | Buy |
56,877
+17,527
| +45% | +$42.6K | ﹤0.01% | 3672 |
|
|
2023
Q4 | $118K | Buy |
39,350
+17,636
| +81% | +$22.9K | ﹤0.01% | 3624 |
|
|
2023
Q3 | $21.3K | Buy |
21,714
+4,578
| +27% | +$6.62K | ﹤0.01% | 3732 |
|
|
2023
Q2 | $23.8K | Buy |
17,136
+2,798
| +20% | +$3.91K | ﹤0.01% | 3766 |
|
|
2023
Q1 | $22.8K | Sell |
14,338
-23,590
| -62% | -$122K | ﹤0.01% | 3788 |
|
|
2022
Q4 | $236K | Buy |
+37,928
| New | +$271K | ﹤0.01% | 3354 |
|
|
2022
Q3 | – | Sell |
-10,840
| Closed | -$69K | – | 4001 |
|
|
2022
Q2 | $69K | Buy |
+10,840
| New | +$61.5K | ﹤0.01% | 3745 |
|
|
2021
Q2 | – | Sell |
-22,721
| Closed | -$637K | – | 4120 |
|
|
2021
Q1 | $637K | Buy |
22,721
+11,161
| +97% | +$329K | ﹤0.01% | 2832 |
|
|
2020
Q4 | $301K | Buy |
11,560
+2,667
| +30% | +$79.9K | ﹤0.01% | 3116 |
|
|
2020
Q3 | $331K | Buy |
8,893
+3,928
| +79% | +$156K | ﹤0.01% | 2891 |
|
|
2020
Q2 | $255K | Buy |
+4,965
| New | +$208K | ﹤0.01% | 3010 |
|
|
2020
Q1 | – | Sell |
-3,975
| Closed | -$237K | – | 3559 |
|
|
2019
Q4 | $237K | Buy |
+3,975
| New | +$179K | ﹤0.01% | 3237 |
|
|
2019
Q3 | – | Sell |
-5,060
| Closed | -$235K | – | 3637 |
|
|
2019
Q2 | $235K | Buy |
+5,060
| New | +$238K | ﹤0.01% | 3145 |
|
|
2018
Q4 | – | Sell |
-6,699
| Closed | -$297K | – | 3593 |
|
|
2018
Q3 | $297K | Buy |
+6,699
| New | +$308K | ﹤0.01% | 3038 |
|
|
2017
Q3 | – | Sell |
-5,200
| Closed | -$241K | – | 3424 |
|
|
2017
Q2 | $241K | Buy |
+5,200
| New | +$191K | ﹤0.01% | 2873 |
|
Other funds holding ESPR
WA
BG
TSC
MG
